RxDoctor Payments Data

Michael Sampson, MD

Internal Medicine · Los Angeles, CANPI 1568466100

Payments from drug & device makers

$6,259in general payments, 2019–2025

Across 328 payments — averaging $19.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$3K
  • Viiv Healthcare Company$2K
  • Johnson & Johnson$365
  • Novo Nordisk$190
  • Janssen Products, LP$60
  • Merck$52
  • plus $135 from 4 others

What the payments were for

  • Food & beverage$6,17099%
  • Education$891%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,259 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$44,021
Medicare patients
34
Services billed
600

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala127$492,341
DovatoDolutegravir Sodium/Lamivudine23$78,989
OzempicSemaglutide53$68,987
TriumeqAbacavir/Dolutegravir/Lamivudi11$36,853
JardianceEmpagliflozin25$29,728
PrezcobixDarunavir/Cobicistat11$24,258
EliquisApixaban18$18,240
Maraviroc13$10,315
Darunavir12$7,006
Testosterone51$4,178
Diflorasone Diacetate11$3,461
Atorvastatin Calcium120$992
Ventolin HfaAlbuterol Sulfate13$720
Tamsulosin Hcl44$550
Silodosin13$540

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy$3,256$492,341127 claims
Viiv Healthcare CompanyDovato, Triumeq$2,200$115,84234 claims
Novo NordiskOzempic$190$68,98753 claims
Johnson & JohnsonPrezcobix$365$24,25811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →